甘李药业：博凡格鲁肽注射液正式启动一项针对肥胖或超重适应症的III期临床试验

Core Viewpoint - Ganli Pharmaceutical (603087) has officially launched a Phase III clinical trial (GRADUAL-3) for its self-developed glucagon-like peptide-1 receptor agonist (GLP-1RA) Bofanglutide (development code: GZR18) targeting obesity or overweight indications [1] Group 1 - The Phase III clinical trial is the third large-scale study for Bofanglutide in the obesity/overweight field [1] - The study will utilize a monthly injection regimen, administering the drug subcutaneously once every four weeks [1] - The aim of the trial is to explore the clinical potential of Bofanglutide injection in controlling and maintaining weight [1]